Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness - PubMed (original) (raw)
Review
Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness
Jan T Poolman et al. Expert Rev Vaccines. 2015.
Free article
Abstract
Vaccines targeting Neisseria meningitidis serogroup B (MenB) have been attempted for 40 years. Monovalent outer membrane vesicle vaccines targeted at epidemic outbreaks have been successfully developed. Newer vaccines aim to induce antibodies to cross-reactive antigens, such as factor H binding protein (rLP2086) or a mix of outer membrane vesicle, factor H binding protein and other minor antigens (4CMenB). The true protective coverage among circulating MenB isolates afforded by these vaccines is unknown. Carefully conducted Phase IV post-implementation evaluations designed to measure specific effectiveness against major circulating MenB clonal lineages are needed to address the critical question of which antigens are linked to protection. Progress with whole-genome sequencing and bio-informatics may allow the composition of antigen mozaics based on two major outer membrane proteins: PorA and FetA.
Keywords: Neisseria meningitidis; immunogenicity; meningococcal antigen typing system; outer membrane vesicle vaccines; vaccine.
Similar articles
- Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS. Donald RG, et al. Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Hum Vaccin Immunother. 2017. PMID: 27960595 Free PMC article. Review. - Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
Bettinger JA, Scheifele DW, Halperin SA, Vaudry W, Findlow J, Borrow R, Medini D, Tsang R; members of the Canadian Immunization Monitoring Program, Active (IMPACT). Bettinger JA, et al. Vaccine. 2013 Dec 17;32(1):124-30. doi: 10.1016/j.vaccine.2013.03.063. Epub 2013 Apr 12. Vaccine. 2013. PMID: 23588089 - The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology.
Masignani V, Pizza M, Moxon ER. Masignani V, et al. Front Immunol. 2019 Apr 16;10:751. doi: 10.3389/fimmu.2019.00751. eCollection 2019. Front Immunol. 2019. PMID: 31040844 Free PMC article. Review. - Challenges and progress in the development of a serogroup B meningococcal vaccine.
Lewis S, Sadarangani M, Hoe JC, Pollard AJ. Lewis S, et al. Expert Rev Vaccines. 2009 Jun;8(6):729-45. doi: 10.1586/erv.09.30. Expert Rev Vaccines. 2009. PMID: 19485754 Review. - Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Gandhi A, Balmer P, York LJ. Gandhi A, et al. Postgrad Med. 2016 Aug;128(6):548-56. doi: 10.1080/00325481.2016.1203238. Epub 2016 Jul 7. Postgrad Med. 2016. PMID: 27467048 Review.
Cited by
- Bactericidal human monoclonal antibody 1B1 shows specificity for meningococcal factor H binding protein variant 2 and displaces human factor H.
Veggi D, Chesterman CC, Santini L, Huang Y, Pacchiani N, Sierra J, Chen L, Laliberte J, Bianchi F, Cozzi R, Frigimelica E, Maione D, Finco O, Bottomley MJ. Veggi D, et al. FASEB Bioadv. 2024 Jun 27;6(8):235-248. doi: 10.1096/fba.2023-00077. eCollection 2024 Aug. FASEB Bioadv. 2024. PMID: 39114449 Free PMC article. - Evolution of Sequence Type 4821 Clonal Complex Hyperinvasive and Quinolone-Resistant Meningococci.
Chen M, Harrison OB, Bratcher HB, Bo Z, Jolley KA, Rodrigues CMC, Bray JE, Guo Q, Zhang X, Chen M, Maiden MCJ. Chen M, et al. Emerg Infect Dis. 2021 Apr;27(4):1110-1122. doi: 10.3201/eid2704.203612. Emerg Infect Dis. 2021. PMID: 33754991 Free PMC article. - Expanding the role of bacterial vaccines into life-course vaccination strategies and prevention of antimicrobial-resistant infections.
Poolman JT. Poolman JT. NPJ Vaccines. 2020 Sep 11;5:84. doi: 10.1038/s41541-020-00232-0. eCollection 2020. NPJ Vaccines. 2020. PMID: 32963814 Free PMC article. Review. - Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1.
Langley JM, Gantt S, Quach C, Bettinger JA, Halperin SA, Mutch J, McNeil SA, Ward BJ, MacKinnon-Cameron D, Ye L, Marty K, Scheifele D, Brown E, Alcantara J; Canadian Immunization Research Network. Langley JM, et al. Emerg Infect Dis. 2020 Mar;26(3):454-462. doi: 10.3201/eid2603.190160. Emerg Infect Dis. 2020. PMID: 32091358 Free PMC article. Clinical Trial. - Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6.
Bianchi F, Veggi D, Santini L, Buricchi F, Bartolini E, Lo Surdo P, Martinelli M, Finco O, Masignani V, Bottomley MJ, Maione D, Cozzi R. Bianchi F, et al. FASEB J. 2019 Nov;33(11):12099-12111. doi: 10.1096/fj.201900374R. Epub 2019 Oct 5. FASEB J. 2019. PMID: 31442074 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources